FUJIFILM Diosynth Biotechnologies vs Pharmaron: CDMO Comparison
How does FUJIFILM Diosynth Biotechnologies compare to Pharmaron?
As of Nov 2026, FUJIFILM Diosynth Biotechnologies: no FDA inspections on file, 35 EMA/MHRA GMP certificates. Signal Score 86.7. Pharmaron: 5 FDA inspections (including 4 NAI, 1 VAI and 0 OAI), 1 EMA/MHRA GMP certificate. Signal Score 86.9. Counts are the established FDA, EMA and MHRA records on each profile. CDMOs cannot pay to change a score.
Side-by-side comparison of FUJIFILM Diosynth Biotechnologies and Pharmaron on independent FDA inspections, EMA and MHRA GMP certificates, clinical-program activity, and CDMO Signal Score. Data sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
Key differences
- Pharmaron has more FDA inspections on record (5 vs 0) — a deeper regulatory paper trail.
- Both maintain clean enforcement records — no FDA OAI classifications or warning letters on file for either CDMO.
- FUJIFILM Diosynth Biotechnologies holds 29 active EMA GMP certificates; Pharmaron does not appear in EudraGMDP.
- FUJIFILM Diosynth Biotechnologies has stronger MHRA / UK coverage (6 compliant certificates vs 1).
Across the cross-modality scorecard, Pharmaron carries the higher composite Signal Score — but the right choice depends on the specific modality, phase, and geography of the program.
Frequently asked: FUJIFILM Diosynth Biotechnologies vs Pharmaron
How does FUJIFILM Diosynth Biotechnologies compare to Pharmaron?
On CDMO Signal's composite Signal Score, FUJIFILM Diosynth Biotechnologies is 87/100 and Pharmaron is 87/100; FUJIFILM Diosynth Biotechnologies has 0 FDA inspections on record vs 5 for Pharmaron; European coverage is 35 active EMA+MHRA certificates for FUJIFILM Diosynth Biotechnologies vs 1 for Pharmaron. Both are tracked in the CDMO Signal directory. The scorecard above breaks down every metric side by side — use it alongside each CDMO's individual profile for the full regulatory and clinical footprint.
Which has the stronger FDA inspection record, FUJIFILM Diosynth Biotechnologies or Pharmaron?
Both FUJIFILM Diosynth Biotechnologies and Pharmaron maintain clean enforcement records on file — no FDA warning letters and no OAI classifications. FUJIFILM Diosynth Biotechnologies has 0 FDA inspections on record; Pharmaron has 5.
How do FUJIFILM Diosynth Biotechnologies and Pharmaron compare on European GMP coverage?
FUJIFILM Diosynth Biotechnologies holds 29 active EMA GMP certificates and 6 MHRA / UK certificates. Pharmaron holds 0 active EMA GMP certificates and 1 MHRA / UK certificate. Use these counts as a proxy for the breadth of each CDMO's European regulatory footprint.
What does the Signal Score gap mean in practice?
FUJIFILM Diosynth Biotechnologies carries a Signal Score of 87/100 and Pharmaron carries 87/100 — essentially tied for Pharmaron. The Signal Score combines quality (FDA inspections + EMA/MHRA GMP), operational performance, financial stability, and capacity intelligence. CDMOs cannot pay to influence their score.
Use the free AI matchmaker to weigh both against your specific requirements — capacity, modality, regulatory record, geography — and surface other qualified options.
Find & compare CDMOs →